Advertisement

Databases and In Silico Tools for Vaccine Design

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 993)

Abstract

In vaccine design, databases and in silico tools play different but complementary roles. Databases collect experimentally verified vaccines and vaccine components, and in silico tools provide computational methods to predict and design new vaccines and vaccine components. Vaccine-related databases include databases of vaccines and vaccine components. In the USA, the Food and Drug Administration (FDA) maintains a database of licensed human vaccines, and the US Department of Agriculture keeps a database of licensed animal vaccines. Databases of vaccine clinical trials and vaccines in research also exist. The important vaccine components include vaccine antigens, vaccine adjuvants, vaccine vectors, and ­vaccine preservatives. The vaccine antigens can be whole proteins or immune epitopes. Various in silico vaccine design tools are also available. The Vaccine Investigation and Online Information Network (VIOLIN; http://www.violinet.org) is a comprehensive vaccine database and analysis system. The VIOLIN database includes various types of vaccines and vaccine components. VIOLIN also includes Vaxign, a Web-based in silico vaccine design program based on the reverse vaccinology strategy. Vaccine information and resources can be integrated with Vaccine Ontology (VO). This chapter introduces databases and in silico tools that facilitate vaccine design, especially those in the VIOLIN system.

Key words

Vaccine Vaccine design Vaccine database VIOLIN vaccine database and analysis system Vaxign Reverse vaccinology Immune epitope Immunoinformatics Vaccine adjuvant 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work has been supported by grant R01AI081062 from the USA National Institute of Allergy and Infectious Diseases (NIAID).

References

  1. 1.
    De Groot AS, Sbai H, Aubin CS et al (2002) Immuno-informatics: mining genomes for vaccine components. Immunol Cell Biol 80:255–269PubMedCrossRefGoogle Scholar
  2. 2.
    Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3:445–450PubMedCrossRefGoogle Scholar
  3. 3.
    He Y, Rappuoli R, De Groot AS, Chen RT (2010) Emerging vaccine informatics. J Biomed Biotechnol 2010:218590PubMedGoogle Scholar
  4. 4.
    Xiang Z, Todd T, Ku KP et al (2008) VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 36:D923–D928PubMedCrossRefGoogle Scholar
  5. 5.
    He Y, Xiang Z, Mobley HL (2010) Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010:297505PubMedGoogle Scholar
  6. 6.
    Bhattacharjee AK, Izadjoo MJ, Zollinger WD et al (2006) Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infect Immun 74:5820–5825PubMedCrossRefGoogle Scholar
  7. 7.
    Ansari HR, Flower DR, Raghava GP (2010) AntigenDB: an immunoinformatics database of pathogen antigens. Nucleic Acids Res 38:D847–D853PubMedCrossRefGoogle Scholar
  8. 8.
    Yang B, Sayers S, Xiang Z, He Y (2011) Protegen: a web-based protective antigen database and analysis system. Nucleic Acids Res 39:D1073–D1078 (database issue)PubMedCrossRefGoogle Scholar
  9. 9.
    Peters B, Sidney J, Bourne P et al (2005) The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 3:e91PubMedCrossRefGoogle Scholar
  10. 10.
    Wang P, Sidney J, Dow C et al (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a ­consensus approach. PLoS Comput Biol 4:e1000048PubMedCrossRefGoogle Scholar
  11. 11.
    Unanue ER (1992) Cellular studies on antigen presentation by class II MHC molecules. Curr Opin Immunol 4:63–69PubMedCrossRefGoogle Scholar
  12. 12.
    Brown JH, Jardetzky TS, Gorga JC et al (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33–39PubMedCrossRefGoogle Scholar
  13. 13.
    Chicz RM, Urban RG, Gorga JC et al (1993) Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27–47PubMedCrossRefGoogle Scholar
  14. 14.
    Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA (2001) High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest 108:1677–1685PubMedGoogle Scholar
  15. 15.
    Plotnicky H, Cyblat-Chanal D, Aubry JP et al (2003) The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 309:320–329PubMedCrossRefGoogle Scholar
  16. 16.
    Bulik S, Peters B, Ebeling C, Holzhutter H (2004) Cytosolic processing of proteasomal cleavage products can enhance the presentation efficiency of MHC-1 epitopes. Genome Inform 15:24–34PubMedGoogle Scholar
  17. 17.
    Peters B, Bulik S, Tampe R et al (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171:1741–1749PubMedGoogle Scholar
  18. 18.
    Nielsen M, Lundegaard C, Lund O, Kesmir C (2005) The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57:33–41PubMedCrossRefGoogle Scholar
  19. 19.
    Stranzl T, Larsen MV, Lundegaard C, Nielsen M (2010) NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 62:357–368PubMedCrossRefGoogle Scholar
  20. 20.
    Rammensee H, Bachmann J, Emmerich NP et al (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219PubMedCrossRefGoogle Scholar
  21. 21.
    Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMedGoogle Scholar
  22. 22.
    De Groot AS, Martin W (2009) Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 131:189–201PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Q, Wang P, Kim Y et al (2008) Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 36:W513–W518PubMedCrossRefGoogle Scholar
  24. 24.
    Lin HH, Zhang GL, Tongchusak S et al (2008) Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 9(Suppl 12):S22PubMedCrossRefGoogle Scholar
  25. 25.
    Gowthaman U, Agrewala JN (2008) In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J Proteome Res 7:154–163PubMedCrossRefGoogle Scholar
  26. 26.
    Enshell-Seijffers D, Denisov D, Groisman B et al (2003) The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J Mol Biol 334:87–101PubMedCrossRefGoogle Scholar
  27. 27.
    Schreiber A, Humbert M, Benz A, Dietrich U (2005) 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. J Comput Chem 26:879–887PubMedCrossRefGoogle Scholar
  28. 28.
    Kulkarni-Kale U, Bhosle S, Kolaskar AS (2005) CEP: a conformational epitope prediction server. Nucleic Acids Res 33:W168–W171PubMedCrossRefGoogle Scholar
  29. 29.
    Sweredoski MJ, Baldi P (2008) PEPITO: improved discontinuous B-cell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics 24:1459–1460PubMedCrossRefGoogle Scholar
  30. 30.
    Blythe MJ, Flower DR (2005) Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 14:246–248PubMedCrossRefGoogle Scholar
  31. 31.
    Reimer U (2009) Prediction of linear B-cell epitopes. Methods Mol Biol 524:335–344PubMedCrossRefGoogle Scholar
  32. 32.
    Rajnavolgyi E, Nagy N, Thuresson B et al (2000) A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes. Int Immunol 12:281–293PubMedCrossRefGoogle Scholar
  33. 33.
    Graham CM, Barnett BC, Hartlmayr I et al (1989) The structural requirements for class II (I-Ad)-restricted T cell recognition of influenza hemagglutinin: B cell epitopes define T cell epitopes. Eur J Immunol 19:523–528PubMedCrossRefGoogle Scholar
  34. 34.
    Fleischmann RD, Adams MD, White O et al (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269:496–512PubMedCrossRefGoogle Scholar
  35. 35.
    Pizza M, Scarlato V, Masignani V et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816–1820PubMedCrossRefGoogle Scholar
  36. 36.
    Sachdeva G, Kumar K, Jain P, Ramachandran S (2005) SPAAN: a software program for prediction of adhesins and adhesin-like proteins using neural networks. Bioinformatics 21:483–491PubMedCrossRefGoogle Scholar
  37. 37.
    He Y, Xiang Z (2010) Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res 6(Suppl 1):S5PubMedCrossRefGoogle Scholar
  38. 38.
    Xiang Z, He Y (2009) Vaxign: a web-based vaccine target design program for reverse vaccinology. Procedia Vaccinol 1(1):23–29CrossRefGoogle Scholar
  39. 39.
    Xiang Z, Courtot M, Brinkman RR et al (2010) OntoFox: web-based support for ontology reuse. BMC Res Notes 3:175PubMedCrossRefGoogle Scholar
  40. 40.
    He Y, Cowell L, Diehl AD et al. (2009) VO: Vaccine ontology. The 1st international conference on biomedical ontology (ICBO 2009). 24-26 July 2009, Buffalo, NY. Nature Precedings. http://precedings.nature.com/documents/3553/version/1. doi:  10.1038/npre.2009.3553.1. Accessed 23 Apr 2012.
  41. 41.
    Xiang Z, He Y (2009) Improvement of PubMed literature searching using biomedical ontology. The 1st international conference on biomedical ontology (ICBO 2009). 24-26 July 2009, Buffalo, NY. Nature Precedings. http://precedings.nature.com/documents/3491/version/1 . doi: 10.1038/npre.2009.3491.1. Accessed 23 Apr 2012
  42. 42.
    Hur J, Xiang Z, Feldman EL, He Y (2011) Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunol 12:49PubMedCrossRefGoogle Scholar
  43. 43.
    Özgür A, Xiang Z, Radev DR, He Y (2011) Mining of vaccine-associated IFN-γ gene interaction networks using the vaccine ontology. J Biomed Semantics 2(suppl 2):S8. doi: 10.1186/2041-1480-2-S2-S8 PubMedCrossRefGoogle Scholar
  44. 44.
    Banai M, He Y (2012) Systems biology and bioinformatics help decipher Brucella antigens involved in clinical manifestation of the disease. Front Cell Infect Microbiol 2:34. doi: 10.3389/fcimb.2012.00034 PubMedCrossRefGoogle Scholar
  45. 45.
    Serruto D, Rappuoli R (2006) Post-genomic vaccine development. FEBS Lett 580:2985–2992PubMedCrossRefGoogle Scholar
  46. 46.
    Mora M, Donati C, Medini D et al (2006) Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr Opin Microbiol 9:532–536PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Unit for Laboratory Animal Medicine, Department of Microbiology and Immunology, Center for Computational Medicine and BioinformaticsUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Comprehensive Cancer CenterUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations

Cite protocol

Buy options